Author: wpGyAwYsMVj2

ORLANDO, Fla., April 10, 2018 /PRNewswire/ — Nutriband Inc. (OTC: NTRB), a Nevada Corporation, is pleased to announce the acquisition of 4P Therapeutics Inc. on April 5, 2018. Nutriband has acquired 100% interest in 4P Therapeutics for a total of $1,900,000 payable in both company stock and cash.  4P Therapeutics will...

Atlanta, Georgia | December 16, 2015. 4P Therapeutics, a drug delivery company with expertise in novel transdermal technologies, announced the successful demonstration of preclinical proof-of-concept for a transdermal patch delivering follicle stimulating hormone (FSH) designed to match the dose and pharmacokinetics of Bravelle®, FSH injection...

NOVEL TRANSDERMAL DELIVERY SYSTEMS FOR TREATMENT OF DIABETES   In the context of a diabetes epidemic, which he characterises in terms of incidence, prevalence and healthcare costs, Alan Smith, PhD, Vice-President, Clinical, Regulatory & Operations, 4P Therapeutics, outlines the stages of Type 2 diabetes treatment, progressing to...

Biotechnology company locates facility in the City of Peachtree Corners (GWINNETT- METRO ATLANTA) June 28, 2013 – Transdermal research and development company, 4P Therapeutics, will join Gwinnett Chamber Economic Development to celebrate the opening of its headquarters facility in the City of Peachtree Corners, Gwinnett County. Bringing an initial...

PRLog (Press Release) Feb. 14, 2013 - Q1 Productions, a leading educational provider for the pharmaceutical industry, will be conducting a webinar entitled "Addressing Challenges in Developing Drug Delivery Systems: Navigating Regulatory Requirements in the US" on Tuesday, February 25 at 1 pm EST. This live...